Targeting kinases in CML CLL

Blood

Volumn 116, Issue 12, 2010, Pages 1999-2000

  Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BCR ABL PROTEIN; CAL 101; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CANCER THERAPY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; IMMUNE SYSTEM; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE;

EID: 77957189914     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-289900     Document Type: Note

References (15)

1. Herman SE, Gordon AL, Wagner AJ, et al. The phosphatidylinositol 3-kinase-delta inhibitor CAL-101 demonstrates promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
2. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol. 2010;28:185-210.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia.NEngl J Med. 2005;352(8):804-815.
4. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6(7):405-418.
5. Kulathu Y, Hobeika E, Turchinovich G, RethM.The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development.EMBOJ. 2008;27(9):1333-1344.
6. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009;69(13):5424-5432.
7. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009; 114(5):1029-1037.
8. Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.
9. Woodland RT, Fox CJ, Schmidt MR, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood. 2008;111(2):750-760.
10. Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL [comment]. Blood. 2008;112(9):3538-3540.
11. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009;114(19):4150-4157.
12. Soond DR, Bjørgo E, Moltu K, et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood. 2010;115(11):2203-2213.
13. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
14. Advani R, Sharman J, Smith S, et al. Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [abstract]. J Clin Oncol. 2010;28:576s.
15. Furman R, Byrd J, Flinn I, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110δd isoform, in patients with relapsed or refractory hematologic malignancies [abstract]. J Clin Oncol. 2010;28:15s.